{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:35:20Z","timestamp":1786736120247,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Taiwan J Ophthalmol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/tjo.tjo_99_17","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T02:24:07Z","timestamp":1537410247000},"page":"168","source":"Crossref","is-referenced-by-count":4,"title":["Interferon-\u03b12a treatment for refractory Beh\u00e7et's disease"],"prefix":"10.4103","volume":"8","author":[{"given":"Wei-Chun","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YungJen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2211-5056.226192-1","doi-asserted-by":"crossref","unstructured":"Zierhut M, Pavesio C, Ohno S, Or\u00e9fice F, Rao NA, editors. Intraocular Inflammation. Germany: Springer; 2016.","DOI":"10.1007\/978-3-540-75387-2"},{"key":"key-10.4103\/2211-5056.226192-2","first-page":"190","volume-title":"Beh\u00e7et's disease","author":"Michelson","year":"1982","journal-title":"Surv Ophthalmol"},{"key":"key-10.4103\/2211-5056.226192-3","first-page":"Ophthalmologic aspects","volume-title":"The eighth Frederick H.Verhoeff Lecture","author":"Mishima","year":"231;","journal-title":"Presented by Saiichi Mishima, MD"},{"key":"key-10.4103\/2211-5056.226192-4","first-page":"1384","volume-title":"WHO-ILAR COPCORD study (Stage 1, urban study) in Iran","author":"Davatchi","year":"2008","journal-title":"J Rheumatol"},{"key":"key-10.4103\/2211-5056.226192-5","first-page":"S31","volume-title":"Patterns and etiologies of uveitis at a tertiary referral center in Taiwan","author":"Chen","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"key-10.4103\/2211-5056.226192-6","first-page":"699","volume-title":"Cytokines and Behcet's disease","author":"Zhou","year":"2012","journal-title":"Autoimmun Rev"},{"key":"key-10.4103\/2211-5056.226192-7","first-page":"285","volume-title":"Management of Beh\u00e7et's syndrome","author":"Ozguler","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"key-10.4103\/2211-5056.226192-8","first-page":"1656","volume-title":"EULAR recommendations for the management of Beh\u00e7et disease","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/2211-5056.226192-9","first-page":"281","volume-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2211-5056.226192-10","first-page":"1733","volume-title":"Azathioprine in severe uveitis of Beh\u00e7et's disease","author":"Saadoun","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key-10.4103\/2211-5056.226192-11","first-page":"1528","volume-title":"Management of Beh\u00e7et disease: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/2211-5056.226192-12","first-page":"1362","volume-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"key-10.4103\/2211-5056.226192-13","first-page":"1575","volume-title":"Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients","author":"D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.4103\/2211-5056.226192-14","first-page":"1010","volume-title":"Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa","author":"Zouboulis","year":"1998","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2211-5056.226192-15","first-page":"293","volume-title":"Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Beh\u00e7et's disease","author":"Wechsler","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"key-10.4103\/2211-5056.226192-16","first-page":"1078","volume-title":"International Study Group for Beh\u00e7et's Disease","author":"Criteria","year":"1990","journal-title":"Lancet"},{"key":"key-10.4103\/2211-5056.226192-17","first-page":"423","volume-title":"Human recombinant interferon Alfa-2a for the treatment of Beh\u00e7et's disease with sight threatening posterior or panuveitis","author":"K\u00f6tter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/2211-5056.226192-18","first-page":"1","volume-title":"Cytokine inhibitors: Soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Beh\u00e7et's disease","author":"D\u00fczg\u00fcn","year":"2005","journal-title":"Rheumatol Int"},{"key":"key-10.4103\/2211-5056.226192-19","first-page":"592","volume-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/2211-5056.226192-20","first-page":"2478","volume-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: An open-label trial","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/2211-5056.226192-21","first-page":"467","volume-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: A randomized placebo-controlled and double-blind study","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2211-5056.226192-22","first-page":"288","volume-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/2211-5056.226192-23","first-page":"837","volume-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/2211-5056.226192-24","first-page":"2796","volume-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et's disease","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/2211-5056.226192-25","first-page":"896","volume-title":"Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et's disease treated with interferon-alpha-2a","author":"Krause","year":"2008","journal-title":"J Rheumatol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:37:35Z","timestamp":1786732655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_99_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"alternative-id":["226192"],"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo_99_17","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}